<DOC>
	<DOCNO>NCT01241409</DOCNO>
	<brief_summary>The purpose study evaluate compare pharmacokinetics ( blood level ) 2 sprinkle capsule formulation rabeprazole sodium administer without food healthy volunteer . In addition , pharmacokinetics 1 formulation rabeprazole sodium evaluate administer food healthy volunteer .</brief_summary>
	<brief_title>A Bioequivalence Study 2 Formulations Rabeprazole Sodium Evaluation Effect Food Rabeprazole Sodium Healthy Adult Volunteers</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( volunteer know treatment/drug take ) , single-dose study 2 formulation rabeprazole sodium healthy adult volunteer . Rabeprazole sodium drug use treat patient Gastroesophageal Reflux Disease ( GERD ) , condition esophagus ( tube throat stomach ) become irritated inflamed result acid back esophagus stomach . All volunteer receive 3 dos study drug ; dose study drug separate least 7 day . Blood sample collect volunteer study measure concentration study drug . Approximately 78 healthy volunteer enrol participate study total approximately 39 day . During study , healthy volunteer make total approximately 4 visit study center . The 4 visit include initial screen visit 3 visit receive study drug . Volunteers require stay study center least 12 hour study drug administration approximately 24 hour study drug administration study procedure perform blood sample collect measure concentration rabeprazole thioether metabolite ( substance produce rabeprazole metabolize body ) plasma ( ie , clear liquid portion blood ) . Volunteers monitor safety throughout study . Healthy volunteer receive single dose study drug 3 treatment period . In treatment period , healthy volunteer receive one 10 mg capsule rabeprazole sodium two 5 mg capsule rabeprazole sodium . The content study drug capsule sprinkle 1 tablespoon applesauce administer orally ( mouth ) healthy volunteer morning fast ( eat ) overnight eat standardized breakfast .</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Have body mass index ( BMI ) 18 30 kg/mÂ² ( inclusive ) , body weight less 50 kg Women must postmenopausal ( spontaneous menses least 2 year ) , surgically sterile , abstinent , , childbearing potential sexually active , practice effective method birth control entry throughout study Women must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screen negative urine pregnancy test Day 1 treatment period Men must agree use adequate contraception method deem appropriate investigator Have normal blood pressure 90 140 mmHg systolic &lt; =90 mmHg diastolic Currently , history medical illness consider Investigator clinically significant illness investigator considers exclude volunteer could interfere interpretation study result Have clinically significant abnormal value hematology , clinical chemistry urinalysis screening deem appropriate investigator Have clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram ( ECG ) screening deem appropriate investigator Have history drug alcohol abuse within past 1 year Have history smoking use nicotinecontaining substance within previous 2 month Have major traumatic surgery within 12 week screen preplanned surgery procedure would interfere conduct study Known allergy study drug excipients formulation Known allergy heparin history heparininduced thrombocytopenia Use concomitant therapy drug metabolize enzyme ( cytochrome P450 ) inducer inhibitor within 6 week study entry entire study Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol , hormonal contraceptive hormonal replacement therapy , within 14 day first dose study drug schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Sprinkle Capsule Formulation</keyword>
	<keyword>Rabeprazole sodium</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Safety</keyword>
</DOC>